Institutional members access full text with Ovid®

Share this article on:

Soluble biomarkers of HIV transmission, disease progression and comorbidities

Leeansyah, Edwina; Malone, David F.G.a; Anthony, Donald D.b; Sandberg, Johan K.a,c

Current Opinion in HIV and AIDS: March 2013 - Volume 8 - Issue 2 - p 117–124
doi: 10.1097/COH.0b013e32835c7134
NEW ADVANCES IN IMMUNOLOGICAL AND VIROLOGICAL MONITORING: Edited by Alan L. Landay and Tae-Wook Chun

Purpose of review The purpose of this study is to survey and synthesize recent progress in soluble biomarkers relevant to HIV-1 disease stages, progression and comorbidities.

Recent findings Soluble biomarkers in plasma and other body fluids provide insight into many aspects of HIV-1 disease. Chemokines and defensins in breast milk and cervicovaginal secretions have been associated with HIV-1 susceptibility and transmission. Acute infection plasma cytokine storm components, including serum amyloid A, IFNγ-induced protein 10, interleukin (IL)-12, interferon-gamma (IFNγ), IL-7 and IL-15, may help predict viral load set-point and the subsequent disease progression. During chronic infection, IL-6, soluble (s)CD14, sCD163, high-sensitivity C-reactive protein, D-dimer, fibrin and hyaluronic acid can help predict comorbidities, and to some extent disease progression and mortality, in patients both on and off antiretroviral therapy. Furthermore, recent results suggest that assessment of combinations of soluble biomarkers may prove more powerful than the single factors alone in predicting disease.

Summary Soluble biomarkers help us understand HIV-1 immunopathogenesis. Integration of many biomarkers derived from a single plasma sample might become a powerful tool to optimize and individualize treatment and care.

aCenter for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

bDepartment of Medicine, Divisions of Infectious and Rheumatic Diseases, Case Western Reserve University, Center for AIDS Research, University Hospitals of Cleveland and VA Medical Center, Cleveland, Ohio, USA

cCenter for HIV Research, Karolinska Institutet, Stockholm, Sweden

Correspondence to Dr Johan K. Sandberg, CIM, Department of Medicine, F59, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden. E-mail: johan.sandberg@ki.se

© 2013 Lippincott Williams & Wilkins, Inc.